Loading
A phase 3 trial of Nivolumab, Ipilimumab in renal cell carcinoma, run by Bristol-Myers Squibb, active and no longer recruiting.
A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer is a phase 3 interventional study registered as NCT03873402 by Bristol-Myers Squibb, with 437 participants enrolled, started 2019-06-21 and due to reach its primary completion in 2027-03-11. Interventions recorded: Nivolumab, Ipilimumab, Ipilimumab placebo. Conditions listed: Renal Cell Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Bristol Myers Squibb, Renal cell carcinoma, Nivolumab, Immune checkpoint inhibitors.
Shares Ipilimumab, Bristol Myers Squibb, Nivolumab, Immune checkpoint inhibitors.
Shares Bristol Myers Squibb, Nivolumab, Immune checkpoint inhibitors.
Shares Ipilimumab, Bristol Myers Squibb, Nivolumab, Immune checkpoint inhibitors.
Shares Ipilimumab, Renal cell carcinoma, Nivolumab, Immune checkpoint inhibitors.
Shares Ipilimumab, Bristol Myers Squibb, Renal cell carcinoma.
Shares Bristol Myers Squibb, Renal cell carcinoma, Nivolumab, Immune checkpoint inhibitors.
Shares Bristol Myers Squibb, Nivolumab, Immune checkpoint inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/